Exploring Future Avenues of Growth for Psychosocial Cancer Care

News
Video

“Psycho-oncology has made remarkable progress; however, there are still critical areas for further development,” Cristiane D. Bergerot, PhD, BS, MS, said.

Psychosocial care needs to be treated as an integral part of standard care in cancer treatment, not as an optional service, Cristiane Decat Bergerot, PhD, BS, MS, stated.

When prompted about the way she’d like to see the field of psycho-oncology grow, Bergerot spoke about accessibility, advocacy efforts, and telehealth. In the modern age, with readily available access to technology, telehealth approaches have become more prevalent for psychosocial care.

For example, a study presented at the 2025 American Psychosocial Oncology Society Meeting showed that telehealth intervention support groups were effective and viable as a strategy for adolescents and young adults with cancer.1

Of 18 patients who completed the acceptability measure, 78% strongly agreed that they would recommend the telehealth group. Additionally, 39% reported feeling very satisfied with their experience in the telehealth group, with 44% feeling satisfied and 17% feeling somewhat satisfied.

CancerNetwork® spoke with Bergerot, the head of supportive care at Grupo Oncoclinicas in Brazil, and a member of the International Psycho-Oncology Society (IPOS), after the announcement of the first ever World Psycho-Oncology Day on April 9, 2025, by IPOS.2

Transcript:

Psycho-oncology has made remarkable progress; however, there are still critical areas for further development. While [psychosocial care is] increasingly recognized, it should be fully integrated into standard care, rather than treated as an optional service because we need to expand access to psycho-oncology to ensure that all patients receive the support they need. Advocacy efforts must also continue to push for the inclusion of psychosocial care in national and global cancer care policies. At the same time, the growing adoptions of telehealth present new opportunities to make psycho-oncology service more accessible and break down many of the barriers to care. Additionally, ongoing research into the effectiveness of various interventions, from digital solutions to community-based programs, will help refine best practices and reinforce the importance of psycho-oncology within healthcare systems.

References

  1. Chan S, Patten J, Lau N. Telehealth group intervention for adolescents and young adults with cancer: a feasibility pilot study. Presented at the 2025 American Psychosocial Oncology Society Meeting; March 5-7, 2025, Pittsburgh, PA. Poster W2.
  2. World Psycho-Oncology Day (WPOD). IPOS. Accessed April 2, 2025. https://tinyurl.com/43c9rr2c

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Related Content